Drug Use Evaluation of Apixaban Based on Attribute Hierarchical Model Weighted Technique for Order Preference by Similarity to Ideal Solution
Objective To promote the rational use of apixaban in clinical practice.Methods According to the drug instruction,the drug use evaluation(DUE)criteria for apixaban was formulated based on relevant guidelines and literature.The indicators of the DUE criteria for apixaban were weighted by the attribute hierarchy model(AHM),the rationality of medical records of patients using apixaban in the hospital from August 2021 to July 2022 was evaluated by the technique for order preference by similarity to ideal solution(TOPSIS)method.Results A total of three primary indicators and 12 secondary indicators were formed.A total of 102 medical records(involving 102 patients)were included,including 52 males and 50 females,with non-valvular atrial fibrillation(52 cases)and prevention of venous thrombosis(30 cases)as the main indications for medication.The secondary indicators with high relative weight coefficients were the indications(0.108),drug conversion(0.107)and contraindications(0.089);the top three secondary indicators with high irrational rate were usage and dosage(61.76%),indications(44.12%)and combined medication(38.24%).The drug use in 15 cases(14.71%),61 cases(59.80%),26 cases(25.49%)were evaluated as rational[relative closeness to optimal plan(Ci)≥0.8],generally rational(0.6≤Ci<0.8),irrational(Ci<0.6)respectively.Conclusion It is feasible to evaluate the rationality of apixaban use based on AHM weighted TOPSIS method.The use of apixaban in this hospital is generally rational,but there are still problems in indications,combined medication,usage and dosage.Clinicians and pharmacists should strengthen the intervention to promote the rational use of apixaban.
attribute hierarchy modeltechnique for order preference by similarity to ideal solutionapixabandrug use evaluationrational drug use